Viridian Therapeutics, Inc. (VRDN)
29.00
-1.39
(-4.57%)
USD |
NASDAQ |
Mar 05, 14:46
Viridian Therapeutics Research and Development Expense (Annual) : 338.47M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Marker Therapeutics, Inc. | 13.47M |
| ADMA Biologics, Inc. | 4.762M |
| Avantor, Inc. | -- |
| Immunovant, Inc. | 360.92M |
| Plus Therapeutics, Inc. | 10.58M |